|
- Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics . . .
The present study confirmed that inhaled BDP has a high systemic contribution from the swallowed fraction A high degree of pulmonary presystemic metabolism for BDP is essential for its topical activity in the lung
- Local versus total systemic bioavailability of beclomethasone . . .
Two safety studies that measured adrenal suppression demonstrated less suppression with HFA-BDP than with a comparable efficacious dose of CFC-BDP It is concluded that L T is a useful parameter that incorporates the systemic contributions of lung deposition and pharmacokinetics
- Extra Fine Hydrofluoroalkane-134A Beclomethasone Aerosols
Concerning systemic effects, limited pharmacokinetic data suggest that 200 μg BDP-HFA yields a slightly greater systemic bioavailability than does a therapeutically equivalent dose of BDP-CFC (400 μg), as suggested by the significantly higher maximum blood concentration of total BDP after inhaled doses of the HFA preparation 1 On the other
- Local versus Total Systemic Bioavailability of Beclomethasone . . .
A high L T is desirable as this implies efficient drug delivery to the target site, and minimization of unwanted activity from non-targeted drug delivery The objective of this publication is to compare L T for CFC and HFA inhaler formulations of beclomethasone dipropionate (BDP)
- Systemic activity of inhaled and swallowed beclomethasone dipropionate . . .
Both inhaled and swallowed fractions produced significant systemic activity, the degree of which depended on the inhaler device used Systemic activity was greater using a dry powder inhaler (52%) than using a metered dose inhaler with a large volume spacer (28%)
- Bioavailability of Beclometasone From Two HFA-BDP Formulations . . . - PubMed
Using a previously developed urinary pharmacokinetic method, we have measured the relative lung and systemic bioavailability of beclometasone dipropionate (BDP) after inhalation from 2 hydrofluroalkane-beclometasone dipropionate (HFA-BDP) formulations when used with a spacer
- Extra Fine Hydrofluoroalkane-134A Beclomethasone Aerosols - CHEST
Concerning systemic effects, limited pharmacokinetic data suggest that 200 mg BDP-HFA yields a slightly greater systemic bioavailability than does a therapeutically equivalent dose of BDP-CFC (400 mg), as suggested by the significantly higher maximum blood concentration of total BDP after inhaled doses of the HFA preparation 1 On the other hand, in
- Inhaled corticosteroids: potency, dose equivalence and therapeutic . . .
A higher potency alone would lead to greater systemic effects but the structural changes that lead to higher potency and a lower dose also result in a lower rate and extent of bioavailability and high clearance
|
|
|